Axsome Therapeutics (AXSM) Cash from Operations (2015 - 2026)
Axsome Therapeutics (AXSM) reported Cash from Operations of 20700000.0 for Q1 2026, up 52.28% on a YoY basis from 13593679.03 in Q1 2025, and down 10.97% sequentially from 18653000.0 in Q4 2025.
Axsome Therapeutics (AXSM) Cash from Operations (2015 - 2026) Analysis & Trends
Axsome Therapeutics (AXSM) has 12 years of Cash from Operations data on file, last reported at 20700000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations rose 52.28% year-over-year to 20700000.0; the trailing twelve-month figure through Mar 2026 stood at 70730000.0 (up 40.22% YoY), and the FY2025 full-year result was 93405000.0, up 27.26% from the prior year.
- Cash from Operations fell to 20700000.0 in Q1 2026, from 18653000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 1046000.0 in Q3 2025 to a low of 55349000.0 in Q2 2023.
- A 5-year average of 29653294.12 and a median of 30110000.0 in 2024 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations tumbled 818.52% in 2024 and soared 105.61% in 2025, its largest moves.
- Tracing AXSM's Cash from Operations over 5 years: stood at 27563000.0 in 2022, then declined by 10.15% to 30362000.0 in 2023, then advanced by 13.7% to 26202000.0 in 2024, then climbed by 28.81% to 18653000.0 in 2025, then slipped by 10.97% to 20700000.0 in 2026.
- Business Quant data shows AXSM's Cash from Operations at 20700000.0 in Q1 2026, 18653000.0 in Q4 2025, and 1046000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Axsome Therapeutics | 12.37 Bn | 12.06 Bn | 176.48 Mn | -20.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.70 Mn |
| Mar 31, 2026 | -20.70 Mn |
| Dec 31, 2025 | -18.65 Mn |
| Dec 31, 2025 | -18.65 Mn |
| Sep 30, 2025 | 1.05 Mn |
| Sep 30, 2025 | 1.05 Mn |
| Jun 30, 2025 | -32.42 Mn |
| Jun 30, 2025 | -32.42 Mn |
| Mar 31, 2025 | -43.38 Mn |
| Mar 31, 2025 | -43.38 Mn |
| Dec 31, 2024 | -26.20 Mn |
| Dec 31, 2024 | -26.20 Mn |
| Sep 30, 2024 | -18.63 Mn |
| Sep 30, 2024 | -18.63 Mn |
| Jun 30, 2024 | -30.11 Mn |
| Jun 30, 2024 | -30.11 Mn |
| Mar 31, 2024 | -53.47 Mn |
| Mar 31, 2024 | -53.47 Mn |
| Dec 31, 2023 | -30.36 Mn |
| Dec 31, 2023 | -30.36 Mn |